Edward Belongia MD
Director, Center for Clinical Epidemiology & Population Health
Center for Clinical Epidemiology & Population Health
1000 North Oak Ave. ML2 Marshfield, WI 54449
- 1974 to 1978:
- BS, Zoology, University of Michigan, Ann Arbor
- 1978 to 1982:
- MD, Michigan State University, East Lansing
- Internal Medicine, University of Wisconsin Hospital and Clinics-Residency, Madison
- 1988 to 1990:
- Epidemic Intelligence Service Officer, Centers for Disease Control and Prevention, U.S. Public Health Service
- 1990 to 1995:
- Public Health Physician, STD Surveillance and Screening Unit, Minnesota Department of Health, Minneapolis
- 1995 to Present:
- Senior Epidemiologist/Director, Center for Clinical Epidemiology & Population Health, Marshfield Clinic Research Institute, Marshfield
- 2009 to Present:
- Adjunct Professor - Department of Population Health Sciences, University of Wisconsin - Madison, Madison
Dr. Belongia is an infectious disease epidemiologist and Director of the Center for Clinical Epidemiology and Population Health at the Marshfield Clinic Research Institute. He leads a research team that has conducted vaccine safety and influenza vaccine effectiveness research for over 12 years in collaboration with CDC. He completed an internal medicine residency at the University of Wisconsin and served as a CDC Epidemic Intelligence Service (EIS) officer. Dr. Belongia is currently a member of the CDC Advisory Committee on Immunization Practices (ACIP), and an Adjunct Professor at the University of Wisconsin—Madison.
Infectious disease epidemiology
McLean HQ, Peterson SH, King JP, Meece JK, Belongia EA. School absenteeism among school-aged children with medically attended acute viral respiratory illness during three influenza seasons, 2012-2013 through 2014-2015. Influenza Other Respi Viruses. 2017 May;11(3):220-229.
PubMed ID: 27885805
Caspard H, Gaglani M, Clipper L, Belongia EA, McLean HQ, Griffin MR, Talbot HK, Poehling KA, Peters TR, Veney N, Ambrose CS. Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children 2-17 years of age in 2013-2014 in the United States. VACCINE. 2016 Jan 14;34(1):77-82.
PubMed ID: 26589519
Belongia EA, Simpson MD, King JP, Sundaram ME, Kelley NS, Osterholm MT, McLean HQ. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis. 2016 Aug;16(8):942-951.
PubMed ID: 27061888
Flannery B, Zimmerman RK, Gubareva LV, Garten RJ, Chung JR, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Ohmit SE, Belongia EA, McLean HQ, Gaglani M, Piedra PA, Mishin VP, Chesnokov AP, Spencer S, Thaker SN, Barnes JR, Foust A, Sessions W, Xu X, Katz J, Fry AM. Enhanced Genetic Characterization of Influenza A(H3N2) Viruses and Vaccine Effectiveness by Genetic Group, 2014-2015. J Infect Dis. 2016 May 6;
PubMed ID: 27190176
McLean HQ, Chow BD, VanWormer JJ, King JP, Belongia EA. Effect of Statin Use on Influenza Vaccine Effectiveness. J Infect Dis. 2016 Jul 28;
PubMed ID: 27471318
Simpson MD, Kieke BA, Sundaram ME, McClure DL, Meece JK, Sifakis F, Gasser RA, Belongia EA. Incidence of Medically Attended Respiratory Syncytial Virus and Influenza Illnesses in Children 6-59 Months Old During Four Seasons. Open Forum Infect Dis.. 2016 Apr;3(2):ofw081.
PubMed ID: 27419158
McLean HQ, Thompson MG, Sundaram ME, Kieke BA, Gaglani M, Murthy K, Piedra PA, Zimmerman R, Nowalk M, Raviotta JM, Jackson ML, Jackson L, Ohmit SE, Petrie JG, Monto A, Meece JK, Thaker S, Thaker S, Clippard J, Spencer SM, Fry A, Belongia EA. Influenza Vaccine Effectiveness in the United States During 2012-13: Variable Protection by Age and Virus Type. JOURNAL OF INFECTIOUS DISEASES. 2015 May;211(10):1529-40.
PubMed ID: 25406334
Belongia EA, Sundaram ME, McClure DL, Meece JK, Ferdinands J, VanWormer JJ. Waning vaccine protection against influenza A (H3N2) illness in children and older adults during a single season. VACCINE. 2015 Jan;33(1):246-51.
PubMed ID: 24962752
McLean HQ, Thompson MG, Sundaram ME, Meece JK, McClure DL, Friedrich T, Belongia EA. Impact of Repeated Vaccination on Vaccine Effectiveness Against Influenza A(H3N2) and B During 8 Seasons. Clin Infect Dis.. 2014 Nov;59(10):1375-85.
PubMed ID: 25270645
McNeil MM, Gee J, Weintraub E, Belongia EA, Lee GM, Glanz JM, Nordin JD, Klein NP, Baxter R, Naleway AL, Jackson L, Omer S, Jacobsen SJ, DeStefano F. The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety. VACCINE. 2014 Sep;32(42):5390-8.
PubMed ID: 25108215
Sundaram ME, Meece JK, Sifakis F, Gasser R, Belongia EA. Medically attended respiratory syncytial virus infections in adults aged >=50 years: clinical characteristics and outcomes. CLINICAL INFECTIOUS DISEASES. 2014 Feb;58(3):342-9.
PubMed ID: 24265361
McLean HQ, Meece JK, Belongia EA. Influenza vaccination and risk of hospitalization among adults with laboratory confirmed influenza illness. VACCINE. 2014 Jan;32(4):453-7.
PubMed ID: 24291201
McClure DL, Kieke BA, Sundaram ME, Simpson M, Meece JK, Sifakis F, Gasser R, Belongia EA. Seasonal incidence of medically attended respiratory syncytial virus infection in a community cohort of adults =50 years old. PLoS One. 2014 Jul;9(7):e102586.
PubMed ID: 25025344
Kieke AL, Borchardt MA, Kieke BA, Spencer SK, Vandermause MF, Smith KE, Jawahir SL, Belongia EA, Marshfield Enterococcal Study Group. Use of streptogramin growth promoters in poultry and isolation of streptogramin-resistant enterococcus faecium from humans. J Infect Dis. 2006 Nov;194(9):1200-1208.
PubMed ID: 17041845